|
 The federal agency said it will share costs with AstraZeneca to
develop a portfolio of drugs to treat illnesses caused by
bioterrorism agents and antibiotic-resistant infections.
The Biomedical Advanced Research and Development Authority of the
HHS will initially provide $50 million, and could pay up to $170
million for development of additional products as part of the deal,
which is for five years.
The first drug candidate to be explored is a combination of two
antibiotics, Aztreonam and Avibactam, known together as ATM-AVI, the
HHS said.
The combination ATM-AVI is being tested in Europe in a mid-stage
study, the agency said.
(Reporting by Vidya L Nathan in Bengaluru; Editing by Sriraj
Kalluvila)
[to top of second column] |
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
